SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence o ...

SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discus ...

AGD delivered ~86,000 whole genomes in 2023, including a unique diverse ancestry cohortExpanded pharma engagement enhances AGD's ability to develop multiomic datasets SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced three new membe ...

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: It is our view that SomaLogic’s considerable cash po ...

Illumina, Inc. (NASDAQ:ILMN) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:30 AM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants David Westenberg - Piper Sandler David Westenberg All right. We're going to get started. Joining me is Illumina's brand-new CEO, and most important question here, can we call you Jacob or Jakob? Jacob Thaysen Well, normally, what I would say is that, my mother would call me Jakob, when we speak English -- Danish a ...

Illumina, Inc. (NASDAQ:ILMN) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Joydeep Goswami - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar [Starts Abruptly] Everyone for joining us this morning. Pleasure to have with us Illumina. From the company, we have CFO Joydeep Goswami and from Investor Relations, we have Salli, and I'm Vijay Kumar, cover Life Science too ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended October 1, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation ...

Illumina, Inc. (NASDAQ:ILMN) Q4 2023 Earnings Conference Call November 9, 2023 5:00 PM ETCompany ParticipantsSalli Schwartz - Vice President of Investor RelationsJacob Thaysen - Chief Executive OfficerJoydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development OfficerConference Call ParticipantsVijay Kumar - Evercore ISIDan Brennan - TD CowenPuneet Souda - Leerink PartnersDan Arias - StifelMichael Ryskin - Bank of AmericaTejas Savant - Morgan StanleyDan Leonard - UBSSung Ji Nam - Sco ...

Summary of Illumina, Inc. Conference Call Company Overview - **Company**: Illumina, Inc. (NASDAQ:ILMN) - **Event**: Morgan Stanley 21st Annual Global Healthcare Conference - **Date**: September 11, 2023 - **Participants**: Joydeep Goswami (CFO), Salli Schwartz (VP of Investor Relations), Tejas Savant (Morgan Stanley) Key Points Leadership Changes - Jacob Thaysen's appointment as CEO is seen as a fresh start for Illumina, emphasizing a renewed focus on core operations and improved margins [2][3] Market Challenges - Illumina has cut guidance for sequencing due to: - Competitive pressures from BGI in China - Macro economic weaknesses - Increased competition and government preference for local sourcing [3][5] - The company does not foresee a recovery in the Chinese market in the near future, citing ongoing competitive intensity and regulatory restrictions [5][6] Competitive Landscape - Competitive pressure is primarily observed in mid-throughput segments, while high-throughput segments remain less affected due to unique value propositions [6][7] - Illumina continues to extract a premium for its innovative products despite price competition [7][8] Product Performance - The NovaSeq X has achieved approximately 10% penetration among existing customers, with a focus on multi-unit customers for higher adoption rates [13][14] - Technical issues during the rollout of the NovaSeq X have been addressed, with most fixes deployed [15][16] Financial Guidance and Margins - Illumina aims for a 25% operating margin target for core operations, though this is described as "stretchy" given current market conditions [32][33] - The company is focused on cost management and productivity initiatives while maintaining commitment to innovation [33][34] GRAIL Divestiture - The divestiture of GRAIL is anticipated, with timing dependent on ongoing legal proceedings and regulatory decisions [34][35] - The company is prepared for various divestiture options based on the outcomes of these cases [36] Future Strategy - Illumina is exploring tuck-in acquisitions and partnerships to enhance its technology offerings, particularly in multiomics and spatial biology [38][39] - The company is committed to balancing hardware sales with value-added applications to capture more market share and improve customer utility [40][41] Additional Insights - Illumina's pricing strategy focuses on value rather than merely competing on price, aiming to address customer pain points and improve overall utility [28][30] - The company acknowledges the need for ongoing innovation to maintain its market leadership and adapt to changing customer needs [30][41]

Illumina, Inc. (NASDAQ:ILMN) Conference Call Summary Industry Overview - The conference is part of the 2023 UBS Life Sciences Conference, focusing on the life sciences industry, particularly genomics and sequencing technologies. Key Points and Arguments Financial Guidance and Performance - Illumina lowered its 2023 core growth guidance from 6%-9% to approximately flat, indicating a significant reduction in expectations [2][3] - Approximately 25% of the variance in guidance is attributed to challenges in China, where recovery has not met expectations [2][3] - The remaining 75% of the variance is due to competitive pricing pressures and slower-than-anticipated consumable purchases related to the NovaSeq X transition [3][5] NovaSeq X Launch and Demand - The NovaSeq X has seen strong demand with about 260 cumulative orders, 40% of which are from clinical customers, indicating a shift in customer base [7][8] - 15% of orders are from customers new to Illumina or high throughput, facilitated by advancements in ambient shipping capabilities [8][10] - The company anticipates a ramp-up in consumable purchases starting in Q4, particularly with the introduction of the 25B flow cell [15][22] Customer Behavior and Market Dynamics - Customers are exhibiting cautious purchasing behavior, leading to longer decision-making times and more disciplined expense management [5][27] - The average pull-through for the NovaSeq 6000 has decreased to $800,000-$900,000, reflecting a faster decline than expected [20][29] - The NextSeq 1K/2K pull-through remains stable at $120,000-$170,000 despite an increase in the installed base [29] Competitive Landscape - Increased competition has led to more aggressive pricing strategies from competitors, impacting Illumina's win rates [3][27] - The company is closely monitoring its competitive position and has seen an acceleration in win rates for mid-throughput products [27] Research and Development Focus - Illumina remains committed to R&D, despite implementing cost-saving measures across various functions, including headcount reductions [36][37] - The company is working on a long-read offering that will be compatible with existing instruments, aiming to provide comprehensive solutions for customers [56][57] Regulatory and Legal Matters - An SEC investigation is ongoing, with the company cooperating and providing requested documents [50] - The GRAIL acquisition is under review, with pending appeals in both the U.S. and EU that could impact the company's future decisions regarding the asset [51][52] Market Opportunities - Illumina sees significant long-term growth potential in clinical markets, which are expected to outpace research markets [46] - The company is focusing on expanding its presence in emerging markets and leveraging the growing interest in liquid biopsy technologies [10][25] Conclusion - Illumina is navigating a challenging macroeconomic environment with cautious customer spending and competitive pressures, but remains optimistic about future growth driven by new product launches and market expansion opportunities [5][43]